100- to 1,000-fold more potent monocyte activator in vitro than standard polysaccharide preparations in clinical cancer immunotherapy (Løbner et al., 2008). Increase of TNFα, IFNγ, and IL-6 levels in blood (Løbner et al., 2008). This evidence concerns the gene IFNG and cancer.